ALK and non-small cell lung carcinoma: Advanced patients with NSCLC not harboring EGFR activating mutations or EML4-ALK rearrangement were enrolled, and the tissue was analyzed by gene expression profile and by the Foundation Medicine NGS sequencing panel.